Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ganirelix Acetate

FDA-approved product (injectable, injection), marketed as Fyremadel, Ganirelix Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ganirelix Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Female infertility
  • Positive regulation of ovulation
  • Reproductive Techniques, Assisted

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-gonadotropin-releasing hormones
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ganirelix Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ganirelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for in Vitro Fertilization: a Prospective Comparative Observational Study

    NCT07732348 · start 2026-09

    Registered record
    Registry ID
    NCT07732348
    Conditions
    Infertility, Female; Ovulation Induction
    Interventions
    Ganirelix; Cetrorelix; Medroxyprogesterone Acetate; Dienogest; Micronized Progesterone; Linzagolix
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2026-12
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Ovulation Induction
    InterventionGanirelix; Cetrorelix; Medroxyprogesterone Acetate; Dienogest +2 more
    PhaseNot recorded
    Registry statusNot yet recruiting

  • hCG Priming in Women With Diminished Ovarian Reserve

    NCT07108621 · start 2026-01-25

    Registered record
    Registry ID
    NCT07108621
    Conditions
    Infertility, Female; Ovarian Reserve; In Vitro Fertilization (IVF)
    Interventions
    Choriongonadotropin alfa (hCG); Isotonic NaCl (Placebo)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01-25
    Completion
    2031-03-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Ovarian Reserve; In Vitro Fertilization (IVF)
    InterventionChoriongonadotropin alfa (hCG); Isotonic NaCl (Placebo)
    PhasePhase 3
    Registry statusRecruiting

  • PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study

    NCT06175832 · start 2025-01-27

    Registered record
    Registry ID
    NCT06175832
    Conditions
    Ovarian Stimulation; Quality of Life; Preimplantation Genetic Testing; Fertility Preservation
    Interventions
    Elonva®; Puregon®; Orgalutran®; Gonapeptyl®; Cerazette®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-01-27
    Completion
    2027-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Stimulation; Quality of Life; Preimplantation Genetic Testing; Fertility Preservation
    InterventionElonva®; Puregon®; Orgalutran®; Gonapeptyl® +1 more
    PhasePhase 4
    Registry statusRecruiting

  • Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women

    NCT06745466 · start 2024-11-15

    Registered record
    Registry ID
    NCT06745466
    Conditions
    Estrogen; Premenopause
    Interventions
    ganirelix acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-11-15
    Completion
    2027-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen; Premenopause
    Interventionganirelix acetate
    PhasePhase 4
    Registry statusRecruiting

  • Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.

    NCT06637189 · start 2024-10-15

    Registered record
    Registry ID
    NCT06637189
    Conditions
    Stimulation in the Ovary; Embryo; Oocyte; Oocyte Retrieval; Fertilization in Vitro; Blastocyst; PGT-A
    Interventions
    Ganirelix; Medroxyprogesterone Acetate 10 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-10-15
    Completion
    2025-12-31
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStimulation in the Ovary; Embryo; Oocyte; Oocyte Retrieval +3 more
    InterventionGanirelix; Medroxyprogesterone Acetate 10 MG
    PhasePhase 4
    Registry statusNot yet recruiting

  • Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility

    NCT06481696 · start 2024-06-01

    Registered record
    Registry ID
    NCT06481696
    Conditions
    Unexplained Infertility
    Interventions
    Resveratrol-based multivitamin supplement; Folic acid; IVF/ICSI; Follitropin Alfa; Ganirelix Acetate 0.5 MG/ML [Fyremadel]; hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-06-01
    Completion
    2025-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnexplained Infertility
    InterventionResveratrol-based multivitamin supplement; Folic acid; IVF/ICSI; Follitropin Alfa +2 more
    PhaseNot applicable
    Registry statusUnknown

  • To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects

    NCT05994378 · start 2023-08-29

    Registered record
    Registry ID
    NCT05994378
    Conditions
    Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
    Interventions
    SHR7280；Ganirelix Acetate Injection simulant; SHR7280 simulant； Ganirelix Acetate Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-08-29
    Completion
    2025-05-02
    Enrolment
    317

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
    InterventionSHR7280；Ganirelix Acetate Injection simulant; SHR7280 simulant； Ganirelix Acetate Injection
    PhasePhase 3
    Registry statusCompleted

  • To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference

    NCT06091436 · start 2023-03-24

    Registered record
    Registry ID
    NCT06091436
    Conditions
    Infertility
    Interventions
    GenSci094; Placebo RecFSH / follitropin alfa; Biological: RecFSH / Follitropin alfa (Days 1 to 7); Placebo GenSci094; RecFSH / Follitropin alfa (Days 8 to hCG); Ganirelix; hCG; Progesterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-03-24
    Completion
    2024-01-29
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionGenSci094; Placebo RecFSH / follitropin alfa; Biological: RecFSH / Follitropin alfa (Days 1 to 7); Placebo GenSci094 +4 more
    PhasePhase 3
    Registry statusCompleted

  • Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer

    NCT04586686 · start 2022-11-01

    Registered record
    Registry ID
    NCT04586686
    Conditions
    Breast Cancer Female
    Interventions
    Ovarian biopsy via laparoscopy; Transvaginal oocyte retrieval
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-11-01
    Completion
    2024-12-31
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female
    InterventionOvarian biopsy via laparoscopy; Transvaginal oocyte retrieval
    PhaseNot applicable
    Registry statusUnknown

  • DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation

    NCT04616729 · start 2022-11-01

    Registered record
    Registry ID
    NCT04616729
    Conditions
    Breast Cancer Female
    Interventions
    Triptorelin 3.75 MG Injection; Transvaginal oocyte retrieval; Triptorelin Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2022-11-01
    Completion
    2025-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female
    InterventionTriptorelin 3.75 MG Injection; Transvaginal oocyte retrieval; Triptorelin Injection
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst

    NCT04993924 · start 2021-05-01

    Registered record
    Registry ID
    NCT04993924
    Conditions
    IVF; Ovarian Cysts
    Interventions
    Cetrorelix Acetate, Ganerelix Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-05-01
    Completion
    2023-03-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF; Ovarian Cysts
    InterventionCetrorelix Acetate, Ganerelix Acetate
    PhasePhase 4
    Registry statusUnknown

  • The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles

    NCT04654741 · start 2020-09-01

    Registered record
    Registry ID
    NCT04654741
    Conditions
    IVF; Infertility
    Interventions
    Medroxyprogesterone Acetate; Ganirelix Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2022-12-31
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIVF; Infertility
    InterventionMedroxyprogesterone Acetate; Ganirelix Acetate
    PhasePhase 4
    Registry statusUnknown

  • Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

    NCT04037605 · start 2020-02-09

    Registered record
    Registry ID
    NCT04037605
    Conditions
    Sleep Restriction
    Interventions
    Ketoconazole Pill (also known as nizoral); Ganirelix; Dexamethasone Pill; Dexamethasone injection; Cosyntropin Injectable Product; Recombinant Human Luteinizing Hormone (also known as luveris); Hydrocortisone Injection (also known as solu-cortef); Gonadorelin (also known as Lutrepulse); Corticorelin (also known as Acthrel); Placebo oral tablet; Saline Solution; Saline solution for injection
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2020-02-09
    Completion
    2026-06-24
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Restriction
    InterventionKetoconazole Pill (also known as nizoral); Ganirelix; Dexamethasone Pill; Dexamethasone injection +8 more
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • "Study of the Effects of Serum and Follicular Fluid Relaxin Levels on Ovarian Function in IVF Cycles"

    NCT04458454 · start 2019-12-02

    Registered record
    Registry ID
    NCT04458454
    Conditions
    Infertility; Reproductive Techniques, Assisted; Oocyte Maturation
    Interventions
    Relaxin ELISA Kit
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-12-02
    Completion
    2020-02-20
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility; Reproductive Techniques, Assisted; Oocyte Maturation
    InterventionRelaxin ELISA Kit
    PhaseNot recorded
    Registry statusCompleted

  • Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response

    NCT04168892 · start 2019-09-20

    Registered record
    Registry ID
    NCT04168892
    Conditions
    Ovarian Response
    Interventions
    150 IU of HMG in patients with age ≤ 35 years; 225 IU of HMG in patients with age > 35 years
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-09-20
    Completion
    2023-01-31
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Response
    Intervention150 IU of HMG in patients with age ≤ 35 years; 225 IU of HMG in patients with age > 35 years
    PhaseNot recorded
    Registry statusCompleted